{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:30Z","timestamp":1790402310561,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"crossref","award":["10.13039\/501100007075"],"award-info":[{"award-number":["10.13039\/501100007075"]}],"id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca","award":["10.13039\/100004325"],"award-info":[{"award-number":["10.13039\/100004325"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1093\/annonc\/mdz414","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T07:40:18Z","timestamp":1571038818000},"page":"1914-1924","source":"Crossref","is-referenced-by-count":189,"title":["Gender medicine and oncology: report and consensus of an ESMO workshop"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-082X","authenticated-orcid":false,"given":"A.D.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oertelt-Prigione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Buclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Dafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.-P.","family":"Dotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7449","authenticated-orcid":false,"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fellay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hocquelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Klinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Letsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdz414_bb0010","doi-asserted-by":"crossref","unstructured":"Oertelt-Prigione SaR-ZV. Sex and Gender Aspects in Clinical Medicine. Springer, London 2012.","DOI":"10.1007\/978-0-85729-832-4"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/ije\/dyg156","article-title":"Genders, sexes, and health: what are the connections\u2014and why does it matter?","volume":"32","author":"Krieger","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1093\/annonc\/mdz414_bb0020","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/embor.2012.87","article-title":"Sex and gender differences in health","volume":"13","author":"Regitz-Zagrosek","year":"2012","journal-title":"EMBO Rep"},{"issue":"22","key":"10.1093\/annonc\/mdz414_bb0025","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/archinte.167.22.2405","article-title":"Symptom presentation of women with acute coronary syndromes: myth vs reality","volume":"167","author":"Canto","year":"2007","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1093\/annonc\/mdz414_bb0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/europace\/eux068","article-title":"The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies","volume":"19","author":"Boriani","year":"2017","journal-title":"Europace"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ehjcvp\/pvw042","article-title":"Gender differences in the effects of cardiovascular drugs","volume":"3","author":"Tamargo","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes","volume":"37","author":"Regitz-Zagrosek","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/17512433.2014.922866","article-title":"Sex and gender influences on pharmacological response: an overview","volume":"7","author":"Franconi","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"26","key":"10.1093\/annonc\/mdz414_bb0050","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.2018.78.3290","article-title":"Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology","volume":"36","author":"Ozdemir","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz414_bb0055","unstructured":"Drug safety: most drugs withdrawn in recent years had greater health risks for women 2001. http:\/\/www.gao.gov\/new.items\/d01286r.pdf (22 October 2019, date last accessed)."},{"issue":"7500","key":"10.1093\/annonc\/mdz414_bb0060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","article-title":"Policy: NIH to balance sex in cell and animal studies","volume":"509","author":"Clayton","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdz414_bb0065","series-title":"Position Paper","article-title":"For a Better Integration of the Gender Dimension in the Horizon 2020 Work Programme","author":"Gender","year":"2016"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0070","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc.2016.30","article-title":"Sexual dimorphism in cancer","volume":"16","author":"Clocchiatti","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0075","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1172\/JCI72718","article-title":"Multifactorial ERbeta and NOTCH1 control of squamous differentiation and cancer","volume":"124","author":"Brooks","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","article-title":"Comprehensive characterization of molecular differences in cancer between male and female patients","volume":"29","author":"Yuan","year":"2016","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1093\/annonc\/mdz414_bb0085","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-18-0362","article-title":"Sex differences in cancer driver genes and biomarkers","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res"},{"issue":"19","key":"10.1093\/annonc\/mdz414_bb0090","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1158\/0008-5472.CAN-18-2219","article-title":"Sexual inequality in the cancer cell","volume":"78","author":"Arnold","year":"2018","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdz414_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semcdb.2016.04.013","article-title":"Dosage compensation of the sex chromosomes and autosomes","volume":"56","author":"Disteche","year":"2016","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ng.3726","article-title":"Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias","volume":"49","author":"Dunford","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0105","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/0008-5472.CAN-06-3895","article-title":"Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers","volume":"67","author":"Gupta","year":"2007","journal-title":"Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz414_bb0110","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1073\/pnas.0905524107","article-title":"Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated","volume":"107","author":"McPherson","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1093\/annonc\/mdz414_bb0115","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1172\/JCI99159","article-title":"Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation","volume":"128","author":"Clocchiatti","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdz414_bb0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0125","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdz414_bb0135","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41418-017-0051-x","article-title":"Sex disparity in cancer: roles of microRNAs and related functional players","volume":"25","author":"Care","year":"2018","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1093\/annonc\/mdz414_bb0140","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2815","article-title":"The X chromosome in immune functions: when a chromosome makes the difference","volume":"10","author":"Libert","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"10.1093\/annonc\/mdz414_bb0145","doi-asserted-by":"crossref","first-page":"eaap8855","DOI":"10.1126\/sciimmunol.aap8855","article-title":"TLR7 escapes X chromosome inactivation in immune cells","volume":"3","author":"Souyris","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1093\/annonc\/mdz414_bb0150","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.18.01668","article-title":"Reply to L. Pala et al","volume":"37","author":"Wagner","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0165","doi-asserted-by":"crossref","first-page":"e0154090","DOI":"10.1371\/journal.pone.0154090","article-title":"Intestinal microbiota is influenced by gender and body mass index","volume":"11","author":"Haro","year":"2016","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdz414_bb0170","article-title":"Sex differences in gut microbiota","volume":"37","author":"Kim","year":"2019","journal-title":"World J Mens Health"},{"issue":"6123","key":"10.1093\/annonc\/mdz414_bb0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.1233521","article-title":"Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity","volume":"339","author":"Markle","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0180","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cmet.2018.09.023","article-title":"The mouse microbiome is required for sex-specific diurnal rhythms of gene expression and metabolism","volume":"29","author":"Weger","year":"2019","journal-title":"Cell Metab"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0185","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0190","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"Shen","year":"2004","journal-title":"J Appl Physiol (1985)"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S0954422412000054","article-title":"Excess body fat in obese and normal-weight subjects","volume":"25","author":"Thomas","year":"2012","journal-title":"Nutr Res Rev"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0200","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1148\/radiol.2018171504","article-title":"Synergy of sex differences in visceral fat measured with CT and tumor metabolism helps predict overall survival in patients with renal cell carcinoma","volume":"287","author":"Nguyen","year":"2018","journal-title":"Radiology"},{"issue":"8","key":"10.1093\/annonc\/mdz414_bb0205","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","article-title":"How to calculate the dose of chemotherapy","volume":"86","author":"Gurney","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdz414_bb0210","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","article-title":"Allometric size: the scientific theory and extension to normal fat mass","volume":"109S","author":"Holford","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2006.11.001","article-title":"Gender differences in drug responses","volume":"55","author":"Franconi","year":"2007","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","article-title":"The current state of knowledge on age, sex, and their interactions on clinical pharmacology","volume":"82","author":"Schwartz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-013-2182-1","article-title":"Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors","volume":"72","author":"Thai","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0250","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1208\/s12248-014-9631-6","article-title":"Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial","volume":"16","author":"Han","year":"2014","journal-title":"AAPS J"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0260","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002800050980","article-title":"Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer","volume":"44","author":"Bressolle","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0265","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdz414_bb0270","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0275","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1023\/A:1026403805756","article-title":"Population pharmacokinetics of temozolomide in cancer patients","volume":"17","author":"Jen","year":"2000","journal-title":"Pharm Res"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0280","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-003-0761-2","article-title":"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies","volume":"53","author":"Mougenot","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0285","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.clpt.6100259","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia","volume":"83","author":"Hing","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0290","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clinthera.2014.12.009","article-title":"Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation","volume":"37","author":"Lim","year":"2015","journal-title":"Clin Ther"},{"issue":"9","key":"10.1093\/annonc\/mdz414_bb0295","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF03261934","article-title":"Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study","volume":"51","author":"Joerger","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1093\/annonc\/mdz414_bb0300","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jcph.543","article-title":"Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure","volume":"55","author":"Berg","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1093\/annonc\/mdz414_bb0305","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00228-013-1580-y","article-title":"Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors","volume":"69","author":"Wu","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0310","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1067\/mcp.2002.129502","article-title":"Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide","volume":"72","author":"Klein","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1093\/annonc\/mdz414_bb0315","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0320","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0325","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0091270009344989","article-title":"Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors","volume":"49","author":"Ma","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0330","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-016-0404-5","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor","volume":"55","author":"Khosravan","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0335","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","article-title":"Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes","volume":"35","author":"Gotta","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0340","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdm498","article-title":"Superior survival of females among 10, 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site","volume":"19","author":"de Vries","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0345","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/jid.2010.354","article-title":"Gender differences in melanoma survival: female patients have a decreased risk of metastasis","volume":"131","author":"Joosse","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"18","key":"10.1093\/annonc\/mdz414_bb0350","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2012.44.5031","article-title":"Sex is an independent prognostic indicator for survival and relapse\/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials","volume":"31","author":"Joosse","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz414_bb0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00008390-199504000-00002","article-title":"Sex-dependent liver metastasis of human melanoma lines in SCID mice","volume":"5","author":"Ladanyi","year":"1995","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1093\/annonc\/mdz414_bb0360","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archderm.142.12.1551","article-title":"Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas","volume":"142","author":"Liu","year":"2006","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1093\/annonc\/mdz414_bb0365","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.bjc.6690637","article-title":"Investigation of female survival benefit in metastatic melanoma","volume":"80","author":"Richardson","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0370","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0002-9610(98)00070-1","article-title":"Superior survival of young women with malignant melanoma","volume":"175","author":"Kemeny","year":"1998","journal-title":"Am J Surg"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0375","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0380","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdz414_bb0385","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2019.37.15_suppl.2517","article-title":"Prognositc and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325\/KEYNOTE-054 pembrolizumab versus placebo trial","author":"Eggermont","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0390","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The epidemiology of esophageal adenocarcinoma","volume":"154","author":"Coleman","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0395","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cgh.2015.10.005","article-title":"The male predominance in esophageal adenocarcinoma","volume":"14","author":"Xie","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0400","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3748\/wjg.v22.i5.1800","article-title":"Gender difference in gastro-esophageal reflux diseases","volume":"22","author":"Asanuma","year":"2016","journal-title":"Wjg"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0405","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jnci\/djy082","article-title":"Associations between prediagnostic concentrations of circulating sex steroid hormones and esophageal\/gastric cardia adenocarcinoma among men","volume":"111","author":"Petrick","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0410","doi-asserted-by":"crossref","first-page":"e0190325","DOI":"10.1371\/journal.pone.0190325","article-title":"Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study","volume":"13","author":"Petrick","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1093\/annonc\/mdz414_bb0415","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-09-0265","article-title":"Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition","volume":"18","author":"Steffen","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdz414_bb0420","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/s12885-018-4786-7","article-title":"A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK","volume":"18","author":"White","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdz414_bb0425","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdz414_bb0430","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/ijc.25596","article-title":"Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study","volume":"128","author":"Lemmens","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdz414_bb0435","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0440","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom","year":"2018","journal-title":"Br J Surg"},{"issue":"2","key":"10.1093\/annonc\/mdz414_bb0445","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.gastro.2017.05.012","article-title":"Sporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancers","volume":"153","author":"Cho","year":"2017","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1093\/annonc\/mdz414_bb0450","article-title":"Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials","volume":"29","author":"Davidson","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz414_bb0455","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2018.1080","article-title":"Association of patient sex with chemotherapy-related toxic effects: a retrospective analysis of the PETACC-3 trial conducted by the EORTC gastrointestinal group","volume":"4","author":"Cristina","year":"2018","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"10.1093\/annonc\/mdz414_bb0460","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1200\/JCO.2018.36.15_suppl.3603","article-title":"Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): a pooled analysis of 28, 636 patients (pts) in the ACCENT database","volume":"36","author":"Wagner","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz414_bb0465","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz414_bb0470","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdz414_bb0475","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2019.37.4_suppl.549","article-title":"Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: analysis of the XELAVIRI (AIOKRK0110) study","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.18.00052","article-title":"Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines, irinotecan, and bevacizumab: a randomized, controlled study-XELAVIRI (AIO KRK0110)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdz414_bb0485","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz414_bb0490","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/EDBK_175447","article-title":"Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it?","volume":"37","author":"Pfreundschuh","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0495","first-page":"19","article-title":"Differences in cancer survival in Canada by sex","volume":"27","author":"Ellison","year":"2016","journal-title":"Health Rep"},{"issue":"10","key":"10.1093\/annonc\/mdz414_bb0500","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/ijc.27889","article-title":"Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France","volume":"132","author":"Monnereau","year":"2013","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1093\/annonc\/mdz414_bb0505","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood-2013-07-517292","article-title":"Inhibition of lymphoma vascularization and dissemination by estrogen receptor beta agonists","volume":"123","author":"Yakimchuk","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mdz414_bb0510","doi-asserted-by":"crossref","first-page":"316.","DOI":"10.1038\/ncponc1124","article-title":"Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies","volume":"5","author":"Klimm","year":"2008","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0515","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00277-003-0727-9","article-title":"Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease","volume":"83","author":"Brosteanu","year":"2004","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2010.245","article-title":"Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols","volume":"25","author":"Burkhardt","year":"2011","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdz414_bb0525","article-title":"German Childhood Cancer Registry - Annual Report 2017","author":"Kaatsch","year":"1980","journal-title":"Institute of Medical Biostatistics Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz 2018"},{"key":"10.1093\/annonc\/mdz414_bb0530","doi-asserted-by":"crossref","first-page":"CIN.S34144","DOI":"10.4137\/CIN.S34144","article-title":"The impact of age and sex in DLBCL: systems biology analyses identify distinct molecular changes and signaling networks","volume":"14","author":"Beheshti","year":"2015","journal-title":"Cancer Inform"},{"key":"10.1093\/annonc\/mdz414_bb0535","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study","volume":"29","author":"Junlen","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"10.1093\/annonc\/mdz414_bb0540","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"Muller","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdz414_bb0545","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mdz414_bb0550","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14860","article-title":"Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients","volume":"179","author":"Pfreundschuh","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1093\/annonc\/mdz414_bb0555","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bcp.13497","article-title":"Gender differences in clinical registration trials: is there a real problem?","volume":"84","author":"Labots","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1093\/annonc\/mdz414_bb0560","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","article-title":"Representation of minorities and women in oncology clinical trials: review of the past 14 years","volume":"14","author":"Duma","year":"2018","journal-title":"JOP"},{"issue":"16","key":"10.1093\/annonc\/mdz414_bb0565","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMp068070","article-title":"The challenge of subgroup analyses-reporting without distorting","volume":"354","author":"Lagakos","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz414\/30151174\/mdz414.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz414\/30740019\/mdz414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz414\/30740019\/mdz414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:12:40Z","timestamp":1623543160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420325643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0923753420325643"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz414","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}